Lu P - Search Results

1

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL. Kadri S, et al. Among authors: lu p. Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9. Blood Adv. 2017. PMID: 29296715 Free PMC article.

2

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL. Cheng S, et al. Among authors: lu p. Blood. 2011 Dec 8;118(24):6342-52. doi: 10.1182/blood-2011-02-333773. Epub 2011 Oct 24. Blood. 2011. PMID: 22025527 Free article.

3

Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Nayar U, et al. Among authors: lu p. Blood. 2013 Oct 17;122(16):2837-47. doi: 10.1182/blood-2013-01-479972. Epub 2013 Aug 13. Blood. 2013. PMID: 23943653 Free PMC article.

4

Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.

Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL. Ma J, et al. Among authors: lu p. Br J Haematol. 2014 Sep;166(6):849-61. doi: 10.1111/bjh.12974. Epub 2014 Jun 24. Br J Haematol. 2014. PMID: 24957109 Free article.

5

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.

Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL. Guo A, et al. Among authors: lu p. Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727. Oncotarget. 2016. PMID: 26717038 Free PMC article.

6

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.

Sharma S, Galanina N, Guo A, Lee J, Kadri S, Van Slambrouck C, Long B, Wang W, Ming M, Furtado LV, Segal JP, Stock W, Venkataraman G, Tang WJ, Lu P, Wang YL. Sharma S, et al. Among authors: lu p. Oncotarget. 2016 Oct 18;7(42):68833-68841. doi: 10.18632/oncotarget.11932. Oncotarget. 2016. PMID: 27626698 Free PMC article.

7

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.

Guo A, Lu P, Coffey G, Conley P, Pandey A, Wang YL. Guo A, et al. Among authors: lu p. Oncotarget. 2017 Feb 21;8(8):12953-12967. doi: 10.18632/oncotarget.14588. Oncotarget. 2017. PMID: 28088788 Free PMC article.

8

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang ML, Wang YL. Lee J, et al. Among authors: lu p. Blood Adv. 2018 Aug 28;2(16):2039-2051. doi: 10.1182/bloodadvances.2018016048. Blood Adv. 2018. PMID: 30115641 Free PMC article.

9

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.

Coffey GP, Feng J, Betz A, Pandey A, Birrell M, Leeds JM, Der K, Kadri S, Lu P, Segal J, Wang YL, Michelson G, Curnutte JT, Conley PB. Coffey GP, et al. Among authors: lu p. Clin Cancer Res. 2019 Feb 15;25(4):1174-1184. doi: 10.1158/1078-0432.CCR-18-1047. Epub 2018 Oct 17. Clin Cancer Res. 2019. PMID: 30333224 Clinical Trial.

10

XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.

Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, Maltsev N, Lu P, Wang YL. Ming M, et al. Among authors: lu p. Mol Cancer Ther. 2018 Dec;17(12):2564-2574. doi: 10.1158/1535-7163.MCT-17-0789-ATR. Mol Cancer Ther. 2018. PMID: 30510142

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,624 results

Search Page